NICHOLE BAUCAN: Open Payments
NPI 1093428542 · LEESVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$344 in 16 payments from 7 companies in 2025. Trend: 2023 $103 · 2024 $66 · 2025 $344
Food & beverage: $344
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $93 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Novo Nordisk Inc | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Alkermes, Inc. | 1 | $20 |
Products named: VRAYLAR, Auvelity, COBENFY, REXULTI, ABILIFY MAINTENA, CAPLYTA, ARISTADA.
Industry payments across LA — which companies pay providers there.
